Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone

This study has been completed.
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00685100
First received: May 23, 2008
Last updated: May 27, 2008
Last verified: May 2008
  Purpose

Background: To identify characteristic morphological changes of the retina, their change over time and the association with visual function after combined photodynamic therapy (PDT) and intravitreal triamcinolone (IVTA).

Methods: In this retrospective study, 40 patients (40 eyes) were treated with PDT and same day IVTA. Optical coherence tomography (OCT), fluorescein angiography (FA) and evaluation of distance visual acuity (VA) were performed. Main outcome measures were the anatomical changes within intra- and subretinal compartments and their detailed analysis and grading.


Condition Intervention Phase
Neovascular Age Related Macular Degeneration
Other: PDT plus intravitreal triamcinolone
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 40
Study Start Date: January 2004
Estimated Study Completion Date: January 2007
Estimated Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: PDT plus intravitreal triamcinolone
    PDT plus intravitreal triamcinolone
    Other Name: PDT plus intravitreal triamcinolone
  Eligibility

Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cnv secondary to age related macular degeneration

Exclusion Criteria:

  • glaucoma, diabetic retinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Priv.Doz. Dr. Stefan Sacu, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT00685100     History of Changes
Other Study ID Numbers: 002
Study First Received: May 23, 2008
Last Updated: May 27, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Medical University of Vienna:
IVTA; CNV; age-related macular degeneration; PDT

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 28, 2014